

151. (Canceled)

152. (Canceled)

153. (Canceled)


154. (Currently Amended) The method of [any one of claims] claim 150[-152], wherein the [therapeutically effective amount is an amount sufficient to deliver] average daily dose is within the range of about [0.001] 0.01 mg to about [25] 0.6 mg compound per kg body weight.

155. (Canceled)

156. (Canceled)

157. (Canceled).

158. (Currently Amended) A method of inhibiting growth of a tumor in an animal comprising:
administering to an animal that has a tumor an amount of a composition comprising a compound having the structure:



wherein R is [hydrogen or] methyl;

wherein the amount [being] is [effective to inhibit growth of the tumor without administration of the composition killing the animal; and

wherein the amount of the composition is an amount] sufficient to deliver an average daily dose of the compound that is within the range of about 0.001 to 0.06 mg [to about 40 mg epothilone] of the compound per kilogram body weight.

159. (Canceled)

160. (Canceled)

161. (New) The method of claim 150 or claim 158, wherein the step of administering comprises administering individual doses not more frequently than once daily.

162. (New) The method of claim 150 or claim 158, wherein the step of administering comprises interrupting individual dose administrations with at least one day of rest.

163. (New) The method of claim 150 or claim 158, wherein the step of administering comprises interrupting individual dose administrations with at least three days of rest.

164. (New) The method of claim 150 or claim 158, wherein the step of administering comprises administering over a period of at least about 6 days.

165. (New) The method of claim 150 or claim 158, wherein the step of administering comprises administering to an animal that has a multidrug resistant tumor.

166. (New) The method of claim 150 or claim 158, wherein the step of administering according to a schedule sufficient to achieve at least about 16% tumor inhibition.

167. (New) The composition of claim 144, wherein the composition is formulated for parenteral delivery.

168. (New) The composition of claim 144, wherein the composition is formulated for oral delivery.
169. (New) The composition of claim 144, wherein the composition comprises an emulsion.
170. (New) The composition of claim 144, wherein the composition comprises an aqueous suspension.